Trehalose and diabetes type 2

Phase 2

Conditions: E11. 9
Type 2 diabetes.
Type 2 diabetes mellitus

Registration Number: IRCT20130829014521N18

Lead Sponsor: ational Institute for Medical Research Development

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 40

Inclusion Criteria

Male or female patients aged between 35 and 85 years
Patients with non-insulin-dependent diabetes mellitus in a stable condition.

Exclusion Criteria

Patients with type 1, type 2, or secondary diabetes receiving insulin therapy.
Patients with renal dysfunction (eGFR less than 30 ml/min).
Patients with severe liver dysfunction or cirrhosis.
Patients regularly receiving oral or injectable corticosteroids.
Patients who were pregnant or nursing or wished to conceive.
Patients participating in this study will be excluded from the study if they need insulin.
Patients who used a-Glucosidase Inhibitors such as acarbose will be excluded from the study.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HOMA-IR alterations. Timepoint: At the beginning and end of the intervention trial (Day 0 and week 12). Method of measurement: HOMA-IR = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.

Secondary Outcome Measures

Name	Time	Method
Fasting plasma glucose (FPG). Timepoint: Baseline and week 12. Method of measurement: Enzymatic assay.;Fasting insulin. Timepoint: Baseline and week 12. Method of measurement: Immunoassay.;HbA1c. Timepoint: Baseline and week 12. Method of measurement: chromatography.;C peptide. Timepoint: Baseline and week 12. Method of measurement: Immunoassay.;Hs-CRP. Timepoint: Baseline and week 12. Method of measurement: Turbidimetric.